KDR and breast cancer: Interestingly, a study combining an anti-VEGFR2 antibody and cancer cell vaccine in a breast cancer mouse model showed that a lower dose of anti-VEGFR2 antibody could normalize the tumor vasculature, modulate the immunosuppressive tumor microenvironment, and synergize with cancer cell vaccine, while a full dose of anti-VEGFR2 could not [38].